

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**January 7, 2019**

Date of report (date of earliest event reported)

---

**Surgery Partners, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**

(State or other jurisdictions of  
incorporation or organization)

**001-37576**

(Commission  
File Number)

**47-3620923**

(I.R.S. Employer  
Identification Nos.)

**310 Seven Springs Way, Suite 500**

**Brentwood, Tennessee 37027**

(Address of principal executive offices) (Zip Code)

**(615) 234-5900**

(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 2.02. Results of Operations and Financial Condition.**

Members of management of Surgery Partners, Inc. (the “Company”) will be meeting with investors as part of the 2019 J.P. Morgan Healthcare Conference on January 7, 8 and 9, 2019. Based on results through November 2018, the Company is reaffirming its previous full-year 2018 guidance of revenue in the range of \$1.75 to 1.8 billion and Adjusted EBITDA in the range of \$230 to \$235 million, and at least \$100 million of capital deployed for acquisitions. This information is included in a Corporate Presentation that may be used for these meetings. The Corporate Presentation is available on the Company’s website at <http://ir.surgerypartners.com/events-and-presentations/presentations>.

The guidance for the fiscal year ended December 31, 2018 is based on results of the Company through November 2018 and is subject to quarter- and year-end adjustments in connection with the completion of customary financial closing procedures, including management’s review and finalization of the results for the full year 2018 and to accounting review procedures by the Company’s independent registered public accounting firm, which have not yet been performed.

The information in this Current Report is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Exchange Act.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **Surgery Partners, Inc.**

By: /s/ Jennifer Baldock  
Jennifer Baldock  
Senior Vice President, General Counsel

Date: January 7, 2019